Search Clinical Trials in the European Union

3-6 months
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
41-60 of 331 trials

Sildenafil for Adults with Univentricular Heart Post-Fontan

We are studying whether adding sildenafil to existing treatments can improve physical performance and quality of life in adults with a univentricular heart after Fontan surgery.

Fontan Procedure and Univentricular Heart3-6 monthsConfirmation phase (III)Standard MedicinesCardiologyHematologyInternal MedicinePediatrics

LiBRA: Lithium for Cognitive Protection After Brain Radiotherapy

We are studying whether lithium can help prevent cognitive problems in children who received brain radiotherapy for cancer. The trial also looks at overall quality of life and safety of the treatment.

Brain Tumor3-6 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesNeurologyOncology

Personalized Anti-Platelet Therapy for Coronary Artery Disease

We are studying whether a genetic test-guided treatment improves blood platelet function in patients with stable coronary artery disease undergoing stenting. This may help determine the best anti-platelet therapy for individual patients.

Stable Coronary Artery DiseaseChronic Coronary Syndrome3-6 monthsMonitoring phase (IV)No PlaceboInvestigational MedicinesCardiologyInternal Medicine

Esophageal Cancer: Preventing Infections After Surgery

We are studying whether a special treatment can reduce the risk of pneumonia and other infections in patients undergoing surgery for esophageal cancer. This may help improve recovery and overall health after the procedure.

Esophageal Cancer3-6 monthsConfirmation phase (III)Monitoring phase (IV)No PlaceboInvestigational MedicinesGastroenterologyInfectious DiseasesOncologyPulmonology

Atopic Eczema: Dupilumab Dosing Study

We are studying how different dosing schedules of dupilumab affect people with controlled atopic eczema. The goal is to see which schedule works best for managing symptoms and improving quality of life.

Atopic Eczema3-6 monthsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteAllergologyDermatology

Diabetic Foot Ulcers: Plasma Rich in Growth Factors Treatment

We are studying whether Plasma Rich in Growth Factors can help heal foot ulcers in diabetic patients better than standard treatments. This trial aims to improve healing outcomes for those with peripheral arterial disease.

Foot Ulcers in Diabetic Patients3-6 monthsMonitoring phase (IV)≤5 visitsNo PlaceboInvestigational MedicinesDermatologyEndocrinology

Atopic Dermatitis: Methotrexate Injection Study

We are testing whether subcutaneous methotrexate can improve skin symptoms in adults with moderate to severe atopic dermatitis compared to a placebo. The study also examines safety and quality of life for participants.

Moderate to Severe Atopic Dermatitis3-6 monthsConfirmation phase (III)6-10 visitsStandard MedicinesAllergologyDermatology

Duchenne Muscular Dystrophy: GIVINOSTAT Study

We are evaluating the long-term safety and effects of GIVINOSTAT in patients with Duchenne Muscular Dystrophy who have previously been treated with this drug. The study aims to understand its impact on muscle strength, respiratory function, and daily life.

Duchenne Muscular Dystrophy3-6 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyOrthopedics and Traumatology

Trigeminal Neuralgia: Botox Treatment Study

We are exploring whether Botox can effectively reduce pain in patients with trigeminal neuralgia compared to a placebo. Additionally, we’re investigating if specific biomarkers can help predict treatment response.

Trigeminal Neuralgia3-6 monthsConfirmation phase (III)≤5 visitsStandard MedicinesNeurology

Alzheimer's Disease: Rotigotine and Rivastigmine Study

We are testing a combination of rotigotine and rivastigmine to see if it improves thinking skills and daily activities in people with mild to moderate Alzheimer's disease. This study compares the new treatment to rivastigmine with a placebo.

Mild to Moderate Alzheimer's Disease3-6 monthsConfirmation phase (III)6-10 visitsStandard MedicinesPartially RemoteNeurology

Chronic Lymphocytic Leukemia: Zanubrutinib and Obinutuzumab Study

We are studying a combination of zanubrutinib and obinutuzumab for patients with untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma. The trial aims to see if this treatment helps achieve better remission rates compared to different schedules of drug administration.

Chronic Lymphocytic Leukemia (CLL)3-6 monthsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Small Cell Lung Cancer: Etoposide-Free Chemotherapy with Durvalumab

We are studying a new treatment combining chemotherapy and durvalumab for patients with extensive stage small cell lung cancer. The trial aims to see how well this treatment works and how it affects patients' quality of life.

Extensive Stage Small Cell Lung Cancer3-6 monthsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

Recurrent Pericarditis in Children: Anakinra vs. Steroids

We are studying whether Anakinra is more effective than steroids for controlling recurrent pericarditis in children who haven't responded to other treatments. This trial aims to help improve care for young patients facing this condition.

Pericarditis3-6 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCardiologyRheumatology

Chronic Open-Angle Glaucoma: Preservative-Free Bimatoprost Eye Drops

We are comparing a new preservative-free eye drop to a standard treatment for patients with chronic open-angle glaucoma or ocular hypertension. The goal is to see if the new formulation is effective and safe for managing eye pressure.

Chronic Open-angle GlaucomaOcular Hypertension3-6 monthsConfirmation phase (III)No PlaceboStandard MedicinesOphthalmology

Sotatercept for Children with Pulmonary Artery Hypertension

We are studying the safety and effects of sotatercept in children aged 1 to under 18 with pulmonary artery hypertension. This research aims to improve treatment options for young patients already receiving standard care.

Pulmonary Arterial Hypertension3-6 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteCardiologyPulmonology

Cancer Treatment: Imipramine for Fascin1 Overexpression

We are studying whether Imipramine can change tumor characteristics in patients with cancer that over-express a protein called Fascin1. This research may help us understand its effects on tumor behavior and markers.

Colon and Rectal Cancer3-6 monthsEfficacy phase (II)Standard MedicinesCost ReimbursementGastroenterologyOncology

Advanced Breast Cancer: Capivasertib with CDK4/6 Inhibitors

We are studying a new treatment combining capivasertib with CDK4/6 inhibitors and fulvestrant for patients with advanced hormone receptor-positive, HER2-negative breast cancer. The goal is to see if this combination improves treatment outcomes compared to standard therapies.

Hormone Receptor-Positive and HER2-Negative Breast Cancer3-6 monthsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

Pulmonary Arterial Hypertension: Treprostinil Sodium for Kids

We are studying the safety and tolerability of a new preservative-free medication for children with pulmonary arterial hypertension. The trial also looks at how it may improve their quality of life and symptoms.

Pulmonary Arterial Hypertension3-6 monthsConfirmation phase (III)≤5 visitsNo PlaceboInvestigational MedicinesPartially RemotePediatricsPulmonology

Blood Pressure Response: Multi-Omics Study

We are exploring how specific biomarkers can predict the effectiveness of blood pressure medications for individuals. This study aims to improve treatment personalization and understand potential side effects.

Essential Hypertension3-6 monthsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementCardiologyInternal Medicine

Dapagliflozin for Patients Undergoing Heart Bypass Surgery

We are studying whether dapagliflozin can help prevent new heart rhythm problems and kidney issues in patients awaiting coronary artery bypass surgery. This research aims to improve recovery and overall outcomes after surgery.

Atrial Fibrillation and Acute Kidney Injury after CABG3-6 monthsConfirmation phase (III)Standard MedicinesCardiologyInternal MedicineNephrology